10-Q · May 15, 2026
Tevogen Bio Holdings Inc. continues to struggle financially as it reports a net loss of $5.4 million for the first quarter of 2026, a notable reduction from a $10.4 million loss in the same period of 2025, primarily due…
Earnings analysis · 10-Q
TVGN earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided excerpt does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed. The most material update is the company’s…
Read full summary
The provided excerpt does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed. The most material update is the company’s failure to meet Nasdaq’s $50 million and $15 million market-value requirements, with compliance deadlines of October 13 and October 14, 2026. Disclosure controls remained ineffective due to a previously reported material weakness, while no material legal proceedings were pending.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No Material Legal Proceedings
The company reported no material legal proceedings pending as of the filing date, August 14, 2026.
-
No Insider Trading Arrangements
No directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
Nasdaq Listing Compliance Risk
Nasdaq notified the company on April 16 and April 17, 2026 that it failed the $50 million minimum market value of listed securities requirement and the $15 million minimum market value of publicly held shares requirement. The compliance deadlines are October 13, 2026 and October 14, 2026, respectively, after a 180-calendar-day remediation period.
-
Material Control Weakness Persists
Disclosure controls and procedures were concluded to be ineffective at the reasonable assurance level as of June 30, 2026 because of a material weakness in internal control over financial reporting previously disclosed in the 2025 Form 10-K; the filing states there were no changes during the quarter that materially affected controls.
Management's outlook
The provided filing excerpt contains no quantitative revenue or EPS outlook; outlook appears deferred to the earnings release or call.
Earlier filings 4
10-K · April 30, 2026
Tevogen Bio Holdings Inc. reported significant challenges in its financial position and operational outcomes over the past year. The company faced compliance issues with Nasdaq regarding market value thresholds and…
10-K · March 31, 2026
Tevogen is a clinical-stage immunotherapy company developing ExacTcell-based allogeneic CD8+ T cell therapies, led by TVGN 489 (COVID-19 / Long COVID). The filing emphasizes Phase 1 safety/persistence data (no…
10-Q · November 14, 2025
Tevogen reported no revenue and a modest sequential improvement in its quarterly operating loss: Q3 net loss was $5,726,812 (net loss per share $0.03) versus $5,884,223 in Q3 2024. Liquidity was bolstered by equity and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.